Achieve Life Sciences Joins Russell 2000® Index
Rhea-AI Summary
Achieve Life Sciences (Nasdaq: ACHV), a late-stage specialty pharmaceutical company developing cytisinicline for nicotine dependence, has been added to the Russell 2000 Index, effective June 26, 2026, as part of the Russell U.S. Indexes reconstitution. Achieve is also a member of the Russell 3000 Index, widely used by institutional investors and index-tracking funds.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – ACHV
On the day this news was published, ACHV gained 3.49%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $22M to the company's valuation, bringing the market cap to $647.78M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
ACHV traded higher ahead of Russell 2000® inclusion, with a +5.61% move and elevated volume. Several biotech peers (ACOG, CHRS, ELDN) also rose, while MIST and NVCT fell, indicating partial but not uniform sector alignment.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 22 | FDA CRL issued | Negative | +5.2% | FDA Complete Response Letter on cytisinicline NDA citing manufacturing and labeling issues. |
| Jun 02 | Board appointments | Positive | -5.1% | Two new directors added as company prepares for NDA resubmission and launch. |
| May 19 | Safety data update | Positive | -6.7% | 52-week ORCA-OL trial showed no new safety signals for cytisinicline. |
| May 12 | Leadership hires | Positive | +7.2% | Commercial and board leadership strengthened with executives from a successful past launch. |
| May 12 | Earnings & financing | Positive | +7.2% | Q1 results plus large private placement and manufacturing partnership updates. |
Recent news often shows divergence, with several positive clinical and corporate updates followed by negative price reactions.
Regulatory & Risk Context
Short positioning is characterized as relatively low, suggesting moderate volatility and limited short-squeeze risk based on current data.
An effective S-3 resale shelf registers 99,037,138 common shares and warrant shares for selling stockholders; the company only receives cash if warrants are exercised.
Market Pulse Summary
This announcement adds ACHV to the Russell 2000®, exposing it to investors benchmarking $12.2 trillion. Recent financings and a sizable resale shelf mean capital access is strong, but potential selling overhang remains a key factor to monitor.
Key Terms
russell 2000® index financial
russell 3000® index financial
russell u.s. indexes financial
market-capitalization rankings financial
AI-generated analysis. Not financial advice.
SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that it has been added to the Russell 2000® Index, effective June 26, 2026, as part of the Russell U.S. Indexes reconstitution. The Company is also a member of the Russell 3000® Index.
Approximately
About Cytisinicline
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products.
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding the timing, nature and outcome of cytisinicline clinical development and regulatory review and approval, data results, the timing, nature and success of Achieve’s commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, the performance of Achieve’s third-party manufacturing partners, the successful launch and commercialization of cytisinicline, and statements concerning Achieve Life Sciences’ future plans and prospects. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those described in Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Achieve Contact
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
425-686-1510
References
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM, doi: 10.1056/EVIDpha2500339.
